1. Generics Bulletin
  2. >>Business
  3. >>Earnings

Earnings Recovery For Nichi-Iko Unlikely Before Full Resumption Of Toyama Shipments

Japanese Generics Giant Still Suffering Following The Events Of 2021

 
• By Chloe Kent

Nichi-Iko still has a long road to recovery ahead as it attempts to get its Toyama plant back on its feet.

Recovery Progressive Bar Loading on Computer Laptop Screen At 38%
A long road to recovery awaits Nichi-Iko • Source: Shutterstock

Earnings recovery for Nichi-Iko Pharmaceutical Co., Ltd. appears unlikely until the full resumption of shipments from its Toyama plant. Despite securing a 9.6% year-on-year revenue rise to ¥47bn ($330m) during its financial Q1 ended 30 June 2022 due to increased sales volume, operating losses expanded to ¥6.5bn compared to ¥4.1bn during the prior year.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Earnings

Despite Multiple Headwinds, Formycon Remains Positive For Its Biosimilars Growth

 
• By Urtė Fultinavičiūtė

Partnering opportunities, paused marketing, approvals, litigations, and many more. Formycon sets out the agenda for 2025, after seeing a bumpy start to the year.

Teva Crib Sheet Reveals Uzedy, Lenalidomide Expectations Ahead Of Q1

 
• By Dean Rudge

Teva is charting a new course under its ‘Pivot to Growth’ strategy, providing a memory aid for investors to better understand the firm’s financials going into 2025.

Alvotech Reveals Ramp-Up In Development As Sales Explode In 2024

 
• By Dave Wallace

With sales and profits shooting up in 2024, Alvotech has revealed plans to rapidly accelerate development to add between four and six programs to its pipeline of biosimilars every year, while at the same time unveiling details of several new brands that it will be seeking to challenge. The firm has also set out longer-term financial targets that anticipate more than trebling its revenues in the next three years.

Henlius Builds Profitability Streak With Second Year In The Black

 
• By Adam Zamecnik

The Chinese player reported its second profitable year in a row, with growth in sales reported across its marketed portfolio and further milestones in the near future.

More from Business